Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.33 |
| ▸ | DRD4 | P21917 | 5/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 5/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7863439 | 0.99 | DRD2 (0.34) | DRD2DRD4HTR1AFAAHHTT | |
| SCHEMBL7870372 | 0.92 | MEN1 (0.38) | DRD2DRD4HTR1AFAAHHTT | |
| SCHEMBL7868688 | 0.91 | ALDH1A1 (0.37) | DRD2DRD4HTR1AFAAHHTT | |
| Hydrochloric Acid SCHEMBL7871764 | 0.90 | ALDH1A1 (0.36) | DRD2DRD4HTR1AFAAHHTT | |
| SCHEMBL7863443 | 0.83 | FAAH (0.38) | HTR1AFAAHHTTBRD4STING1 | |
| Hydrochloric Acid SCHEMBL7872445 | 0.82 | FAAH (0.38) | DRD2HTR1AFAAHHTTBRD4 | |
| SCHEMBL7875380 | 0.81 | HTR1A (0.48) | DRD2HTR1ABRD4STING1ADORA3 | |
| Hydrochloric Acid SCHEMBL7870310 | 0.80 | HTR1A (0.48) | DRD2HTR1ABRD4STING1ADORA3 | |
| SCHEMBL7871635 | 0.80 | EPHX1 (0.37) | HTTCNR1CNR2 | |
| SCHEMBL7872390 | 0.80 | TDP1 (0.32) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010051631-A1 | Tricyclic compounds, their production and use | TAKATANI MUNEO (JP) | 2001-12-13 | — | — | US | disclosed |
| US-6251905-B1 | Tricyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-0771319-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996002542-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051631-A1 | Tricyclic compounds, their production and use | PDGFA, HGF, REN | DRD2 1720/4885DRD4 1994/4885HTR1A 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.